Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated May 22, 2026, serves as a notice regarding the upcoming publication of financial results. The filing confirms that the Company's Q2 2026 results are scheduled for release via the London Stock Exchange on Tuesday, July 28, 2026. The announcement will also include an update on portfolio growth opportunities.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural notice and does not contain the actual financial performance data for the period.
Material Changes
No material changes to financial performance are reported in this filing as the results for Q2 2026 have not yet been published. The document outlines the indicative schedule for results announcements and dividend dates for the remainder of the 2026 financial year.
Guidance, Outlook, and Risks
Management indicates that the upcoming Q2 2026 results announcement will provide an update on portfolio growth opportunities. The filing notes that the listed dates for results announcements, ex-dividend dates, record dates, and dividend payments are indicative and may be subject to change. No specific risks or contingencies are detailed in this notice.
Key Facts for Investors to Verify
- Q2 2026 results announcement date: Tuesday, July 28, 2026.
- Q2 2026 Ordinary Shares ex-dividend date: Thursday, August 13, 2026.
- Q2 2026 American Depositary Shares ex-dividend date: Friday, August 14, 2026.
- Q2 2026 dividend payable date: Thursday, October 8, 2026.
- All listed dates are indicative and subject to change.